Antag Therapeutics is developing first-in-class GIPR antagonist therapies to address unmet medical needs in obesity treatment. We welcome inquiries from potential collaborators, investors, and scientific partners interested in our novel approach to metabolic disease.

Antag Therapeutics head office

COBIS
Ole Maaløes Vej 3

2200 Copenhagen N

Denmark
antag@antagtx.com

We are always seeking experienced professionals to join our team as we advance our compound through clinical development.

Our focus is on rigorous science, clinical excellence, and bringing meaningful and better therapeutic options to patients with obesity and metabolic disorders.

For current opportunities and general inquiries, please contact us at antag@antagtx.com.